Gm04981

De-identified fresh frozen human skeletal muscle tissues were purchased from ProteoGenex Inc. The study protocol was approved by the Institutional Review Board of MD Anderson Cancer Center, University of Texas. Clinical information is summarized in Supplementary Table 1.
All hiPSC studies were approved by HEIP Stem Cell committee of the University of Texas, MD Anderson Cancer Center. De-identified human BMD patient’s donor fibroblasts cells (GM04569, GM05089, GM02298 and GM04981) and healthy donor fibroblast cells (GM09503) were obtained from Coriell Institute and reprogramed to iPS cells at Human Stem Cell Core (Baylor College of Medicine). The human DMD patients donor iPS cells (GM25313) were obtained from Coriell Institute. Clinical information is summarized in Supplementary Table 1. IPS cells were cultured on hESC-Qualified Matrigel (Corning) coated plates and maintained in feeder-free mTeSR™1 medium (Stemcell Technologies). The pluripotency of these iPSCs were verified using Human Pluripotent Stem Cell Functional Identification Kit (R&D Systems, Catalog # SC027). Antibodies with dilution information are listed in Supplementary Table 10. hiPS cells were differentiated to cardiomyocytes and skeletal muscle cells using the STEMdiff™ Cardiomyocyte Differentiation Kit (Stemcell Technologies) and skeletal muscle differentiation protocol previously described^{54 (link)}.